Company intelligence / Profile preview
Tune Therapeutics
Durham, North Carolina, United Statestunetx.com ↗
- Ownership
- Private
- Employees
- ~140
- Development stage
- Phase 1
01
Overview
The company’s lead candidate, Tune‑401 for chronic Hepatitis B virus infection, entered clinical trials in New Zealand and Hong Kong in late 2024. The approach uses the TEMPO platform to silence viral DNA without altering the host genome. Early results or detailed outcomes have not yet been reported publicly as of early/mid‑2025.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Epigenetic editing/epi-editing (epigenome modulation)Gene regulation/tuning (non-permanent, non-DNA-cutting)Lipid nanoparticle delivery
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Acuitas Therapeutics Inc. (provides lipid nanoparticle technology for drug delivery)
Beyond the preview
Go deeper on Tune Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tune Therapeutics.